To browse Academia. Introduction: Chronic obstructive pulmonary disease COPD with hypertension occupy a leading position in morbidity and mortality in the world. The question of studying a single pathological way of their development, the search for diagnostic markers and therapeutic targets in this comorbid pathology remains relevant. The aim of the study was to study cardiopulmonary parameters in patients with chronic obstructive pulmonary disease with concomitant hypertension, depending on the level of vasoactive intestinal peptide VIP.
Materials and methods: 99 patients with COPD GOLD 2 were examined, 54 of whom had concomitant hypertension II stage, in which the dependence of lipid metabolism, spirometry and hemodynamic parameters, depending on the level of VIP in blood serum.
Results and conclusions: It was established that the smallest values of VIP and the greatest changes in cardiopulmonary parameters, lipid metabolism were found in the cohort of persons with concomitant hypertension.
Respiration; international review of thoracic diseases, Vasoactive intestinal peptide VIP is the most abundant neuropeptide in the lung. VIP has been linked to pulmonary arterial hypertension and hypoxia.
We aimed to assess circulating VIP levels at exacerbation and at stable chronic obstructive pulmonary disease COPD and to evaluate the diagnostic performance in a well-characterized cohort of COPD patients. Serum VIP levels were determined by enzyme-linked immunosorbent assay. Diagnostic accuracy was analyzed by receiver operating characteristic curve and area under the curve AUC.
